558 related articles for article (PubMed ID: 30603741)
1. Chimeric antigen receptor modified T-cells for cancer treatment.
Han X; Wang Y; Han WD
Chronic Dis Transl Med; 2018 Dec; 4(4):225-243. PubMed ID: 30603741
[TBL] [Abstract][Full Text] [Related]
2. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
3. Strategies for Dodging the Obstacles in CAR T Cell Therapy.
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F; Khoshtinat Nikkhoi S
Front Oncol; 2021; 11():627549. PubMed ID: 33869011
[TBL] [Abstract][Full Text] [Related]
4. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
5. Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia.
Wei G; Ding L; Wang J; Hu Y; Huang H
Exp Hematol Oncol; 2017; 6():10. PubMed ID: 28413717
[TBL] [Abstract][Full Text] [Related]
6. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
7. Current challenges and emerging opportunities of CAR-T cell therapies.
Abreu TR; Fonseca NA; Gonçalves N; Moreira JN
J Control Release; 2020 Mar; 319():246-261. PubMed ID: 31899268
[TBL] [Abstract][Full Text] [Related]
8. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy.
Riegler LL; Jones GP; Lee DW
Ther Clin Risk Manag; 2019; 15():323-335. PubMed ID: 30880998
[TBL] [Abstract][Full Text] [Related]
9. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
10. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
11. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Lee DW; Santomasso BD; Locke FL; Ghobadi A; Turtle CJ; Brudno JN; Maus MV; Park JH; Mead E; Pavletic S; Go WY; Eldjerou L; Gardner RA; Frey N; Curran KJ; Peggs K; Pasquini M; DiPersio JF; van den Brink MRM; Komanduri KV; Grupp SA; Neelapu SS
Biol Blood Marrow Transplant; 2019 Apr; 25(4):625-638. PubMed ID: 30592986
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies.
Lu YJ; Chu H; Wheeler LW; Nelson M; Westrick E; Matthaei JF; Cardle II; Johnson A; Gustafson J; Parker N; Vetzel M; Xu LC; Wang EZ; Jensen MC; Klein PJ; Low PS; Leamon CP
Front Oncol; 2019; 9():151. PubMed ID: 30941303
[TBL] [Abstract][Full Text] [Related]
13. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.
Polgárová K; Otáhal P; Šálek C; Pytlík R
Front Oncol; 2022; 12():876758. PubMed ID: 35600381
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Cooper ML; DiPersio JF
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
Front Immunol; 2017; 8():1850. PubMed ID: 29312333
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]